Google.org

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

Solstice is a company dedicated to making renewable energy accessible to all Americans through community-shared solar power. Founded in 2016 and headquartered in Cambridge, Massachusetts, Solstice provides comprehensive customer solutions for shared solar, including subscriber aggregation and management services aimed at solar developers, utilities, and other providers. By employing community organizing techniques along with its innovative online marketplace, Solstice aggregates consumer demand to facilitate the deployment of community solar projects. This approach enables renters and homeowners with non-optimal roofs to participate in solar energy, allowing them to save on utility bills without upfront costs. Solstice is driven by a commitment to energy equity, striving to ensure that affordable renewable energy is available to every household, regardless of income or credit status. The company has been recognized with multiple awards for its contributions to clean energy and entrepreneurship.

If a technical career is what you seek, Benjamin Franklin Institute of Technology (BFIT) provides you with the education you need to pursue your professional goals. For over a century, BFIT has been one of Boston’s top career colleges. The institute has helped students reach their potential through technical education programs in the following types of fields: * Automotive Technology * Computer Technologies * Electronics Engineering Technology * Mechanical Engineering Technology * Medical Electronics Engineering Technology * Ophthalmic Assisting The Academic Success Center at BFIT ensures that students are given the resources and tools they need to excel in their academics and training. Some of the services offered through the center include: academic advising, special accommodations, tutoring, and more. College life at BFIT is filled with exciting experiences. From dorm life and council leadership to community service and intramural sports, the school encourages students to get involved in extracurricular activities. Applicants who are interested in admissions to the school must submit Accuplacer test results, an application, recommendation letters, and official transcripts for review. The school will waive its enrollment fee for any admissions applications submitted online. Merit and need-based financial aid exists in many forms at BFIT for those who qualify and are looking for tuition assistance.

Delphia Therapeutics, headquartered in Boston, USA, is a biotechnology company focused on developing innovative cancer treatments. It operates a laboratory where researchers study cancer-driving pathways to create targeted therapies. The company's approach involves selectively over-activating certain cancer-linked cell signaling pathways, making tumor cells unsustainable and enabling more effective cancer treatment for patients.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Superplastic, Inc. is a character-based product and entertainment company founded in 2017 and based in Burlington, Vermont. The company specializes in manufacturing and marketing limited edition art toys, apparel, games, and animation, featuring unique characters created in collaboration with renowned artists. Superplastic leverages the principles of effort and scarcity to enhance the value of its offerings, creating exclusive works of art for a select audience. The company also operates a platform that engages customers through various media, including animated videos and music, enabling interactions with its synthetic superstars in innovative ways. Products are primarily sold online, reflecting a modern approach to retail and entertainment.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Fractyl Health, based in Lexington, Massachusetts, specializes in developing innovative medical device solutions for metabolic diseases, particularly type 2 diabetes and obesity. The company’s primary offering, Revita DMR, is a minimally invasive therapy that utilizes hydrothermal ablation to rejuvenate the duodenal lining, which can become compromised due to high-fat and high-sugar diets. By focusing on durable disease-modifying therapies rather than just symptomatic management, Fractyl Health aims to address the underlying causes of metabolic diseases, improving patient outcomes and reducing healthcare burdens. Founded in 2010 and originally named MedCatalyst, Inc., the company envisions a future where less invasive, device-based therapies provide effective solutions for large populations affected by metabolic disorders.

Merlin Labs is an innovative company focused on creating autonomous flight technology for advanced air travel, primarily utilizing fixed-wing aircraft. Founded in 2018 and headquartered in Boston, Massachusetts, the company develops a sophisticated aircraft autonomy system that employs artificial intelligence and machine learning, akin to the technology used in driverless cars. This system aims to facilitate the pilotless transportation of goods and eventually people, establishing a new infrastructure for aerial mobility.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics, catering to global enterprises. Founded in 2011 and headquartered in San Francisco, California, the company offers the SingleStore Managed Service, a cloud database-as-a-service that enables analytics on various cloud platforms, alongside SingleStore DB, a distributed SQL database suitable for both bare metal and hybrid cloud environments. The company focuses on operational analytics and supports modern data platform solutions that encompass IoT analytics, risk management, and customer engagement. SingleStore serves a diverse range of industries, including financial services, media communications, energy and utilities, government, and retail. The company, previously known as MemSQL Inc., rebranded to SingleStore, Inc. in October 2020 and also maintains offices in Seattle, Boston, Portland, Lisbon, and London.

FYTO, Inc. is a company based in Cambridge, Massachusetts, that focuses on developing plant-based feed production systems aimed at enhancing the sustainability of agriculture. Founded in 2019, FYTO specializes in creating nutrient-dense crops that require minimal resources, alongside cultivation and harvesting systems designed to ensure quality and consistency. The company's offerings include a variety of agricultural products such as animal feed, plant-based proteins, nutritional supplements, and bio-fertilizers. By adopting climate-friendly practices and methodologies, FYTO aims to support farmers globally in achieving improved economic and environmental outcomes in their agricultural operations.

Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.

Celsius Therapeutics is a biotechnology company focused on developing precision medicines for patients with cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a team of scientists, technologists, computational biologists, clinicians, and drug hunters. Utilizing single-cell genomic analysis and machine learning techniques, Celsius Therapeutics aims to discover and create innovative therapies that can lead to significant improvements in patient outcomes. The company's research efforts are centered on identifying new drug candidates that address unmet medical needs in the therapeutic landscape.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

RightHand Robotics, Inc. specializes in the manufacturing of robotic order-picking systems designed to enhance supply chain logistics and order fulfillment across various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015, the company is headquartered in Cambridge, Massachusetts, with an additional office in Frankfurt, Germany. RightHand Robotics offers innovative solutions like the ReFlex SF, which features a 3D-printed palm equipped with advanced servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that aids in gentle object handling. Their technology enables robots to automatically grasp a wide range of items from bins and cases without the need for extensive data entry or parameter tuning, making their systems cost-effective and adaptable to changing business needs.

Scandit AG is a technology company specializing in barcode scanning software solutions and mobile computer vision. Founded in 2009 and headquartered in Zurich, Switzerland, with additional offices in the United States and Europe, Scandit develops applications that enable high-performance scanning on various smart devices, including smartphones, tablets, and wearables. Its offerings include the Barcode Scanner SDK, which transforms devices into enterprise-grade scanning tools, and the MatrixScan feature that enhances recognition processes for retail and logistics. Scandit's solutions are utilized across multiple industries, such as retail, healthcare, and manufacturing, to support applications like mobile shopping, inventory management, and asset tracking. The company's technology also incorporates augmented reality capabilities, providing real-time information overlays to improve user experience. Scandit aims to enhance operational efficiency and customer satisfaction for organizations, serving a diverse clientele that includes well-known brands.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

Mabl Inc. is an intelligent test automation company based in Boston, Massachusetts, founded in 2016. It offers an automated testing service that leverages machine learning to identify regressions and automatically fix broken tests. The platform provides scriptless testing and integrates seamlessly into the continuous integration and continuous deployment (CI/CD) development lifecycle, allowing software teams to create and maintain reliable, auto-healing tests. By streamlining the testing process, Mabl enables organizations to enhance the speed and quality of their software releases, facilitating faster delivery of high-quality applications while helping developers and testers address bugs before they reach production.

RightHand Robotics, Inc. specializes in the manufacturing of robotic order-picking systems designed to enhance supply chain logistics and order fulfillment across various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015, the company is headquartered in Cambridge, Massachusetts, with an additional office in Frankfurt, Germany. RightHand Robotics offers innovative solutions like the ReFlex SF, which features a 3D-printed palm equipped with advanced servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that aids in gentle object handling. Their technology enables robots to automatically grasp a wide range of items from bins and cases without the need for extensive data entry or parameter tuning, making their systems cost-effective and adaptable to changing business needs.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics, catering to global enterprises. Founded in 2011 and headquartered in San Francisco, California, the company offers the SingleStore Managed Service, a cloud database-as-a-service that enables analytics on various cloud platforms, alongside SingleStore DB, a distributed SQL database suitable for both bare metal and hybrid cloud environments. The company focuses on operational analytics and supports modern data platform solutions that encompass IoT analytics, risk management, and customer engagement. SingleStore serves a diverse range of industries, including financial services, media communications, energy and utilities, government, and retail. The company, previously known as MemSQL Inc., rebranded to SingleStore, Inc. in October 2020 and also maintains offices in Seattle, Boston, Portland, Lisbon, and London.

Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing novel cancer therapies that target monoPARP proteins, which are essential regulators of cancer survival mechanisms. Established in 2015, Ribon is leveraging insights from its scientific founders and an experienced management team to create a proprietary drug discovery platform aimed at understanding the molecular actions and biological functions of monoPARPs. This platform enables the development of small molecule inhibitors designed to disrupt cancer cells' abilities to withstand stress, potentially leading to innovative treatments for cancer and other diseases. The company is supported by notable life science investors, positioning it for growth in the biopharmaceutical sector.

Merlin Labs is an innovative company focused on creating autonomous flight technology for advanced air travel, primarily utilizing fixed-wing aircraft. Founded in 2018 and headquartered in Boston, Massachusetts, the company develops a sophisticated aircraft autonomy system that employs artificial intelligence and machine learning, akin to the technology used in driverless cars. This system aims to facilitate the pilotless transportation of goods and eventually people, establishing a new infrastructure for aerial mobility.

Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative adeno-associated virus (AAV) vectors for gene therapy applications. Founded in 2018, the company employs an artificial intelligence-powered platform that integrates next-generation DNA synthesis, high-throughput sequencing, and machine learning. This advanced approach allows Dyno Therapeutics to design and optimize cell-targeting capsids, which are crucial for the effective and safe delivery of gene therapies. By leveraging its technology, the company aims to provide medical researchers with novel AAV vectors that enhance the efficacy of in vivo therapeutic solutions.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Treeline Biosciences is a biotechnology company established in 2021 and based in Stamford, Connecticut. The company focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. Utilizing a comprehensive drug discovery platform, Treeline combines mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science to create innovative therapeutic solutions. Through its research and development efforts, Treeline aims to provide effective treatments to improve patient outcomes in oncology and beyond.

Tend is a modern dental care provider that aims to transform the patient experience by offering personalized and hassle-free services. Launched in October 2019, the company has established 25 locations across major cities including New York, Washington DC, Boston, Atlanta, Nashville, and Connecticut. Tend focuses on patient happiness in a calm and inviting environment, leveraging technology and a hospitality-driven approach alongside a highly skilled clinical team. By prioritizing comfort and efficiency, Tend has become one of the top-rated full-service dental practices in the country, employing over 650 team members to support its mission of delivering quality oral health care.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

TScan Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative T cell receptor (TCR) engineered therapies to combat various cancers. Based in Waltham, Massachusetts, the company focuses on TCR-T therapies for both liquid cancers and solid tumors. Its lead candidates, TSC-100 and TSC-101, are designed to address hematologic malignancies, specifically targeting residual leukemia and preventing relapse after hematopoietic stem cell transplantation. In addition, TScan is advancing a multiplexed TCR-T therapy program aimed at treating a range of solid tumors. The company's proprietary platform identifies clinically relevant T cell antigens and minimizes off-target effects, enhancing the precision of its therapies. Founded in 2018, TScan Therapeutics is committed to improving outcomes for patients with serious diseases.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics, catering to global enterprises. Founded in 2011 and headquartered in San Francisco, California, the company offers the SingleStore Managed Service, a cloud database-as-a-service that enables analytics on various cloud platforms, alongside SingleStore DB, a distributed SQL database suitable for both bare metal and hybrid cloud environments. The company focuses on operational analytics and supports modern data platform solutions that encompass IoT analytics, risk management, and customer engagement. SingleStore serves a diverse range of industries, including financial services, media communications, energy and utilities, government, and retail. The company, previously known as MemSQL Inc., rebranded to SingleStore, Inc. in October 2020 and also maintains offices in Seattle, Boston, Portland, Lisbon, and London.

Superplastic, Inc. is a character-based product and entertainment company founded in 2017 and based in Burlington, Vermont. The company specializes in manufacturing and marketing limited edition art toys, apparel, games, and animation, featuring unique characters created in collaboration with renowned artists. Superplastic leverages the principles of effort and scarcity to enhance the value of its offerings, creating exclusive works of art for a select audience. The company also operates a platform that engages customers through various media, including animated videos and music, enabling interactions with its synthetic superstars in innovative ways. Products are primarily sold online, reflecting a modern approach to retail and entertainment.

Tend is a modern dental care provider that aims to transform the patient experience by offering personalized and hassle-free services. Launched in October 2019, the company has established 25 locations across major cities including New York, Washington DC, Boston, Atlanta, Nashville, and Connecticut. Tend focuses on patient happiness in a calm and inviting environment, leveraging technology and a hospitality-driven approach alongside a highly skilled clinical team. By prioritizing comfort and efficiency, Tend has become one of the top-rated full-service dental practices in the country, employing over 650 team members to support its mission of delivering quality oral health care.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

Scandit AG is a technology company specializing in barcode scanning software solutions and mobile computer vision. Founded in 2009 and headquartered in Zurich, Switzerland, with additional offices in the United States and Europe, Scandit develops applications that enable high-performance scanning on various smart devices, including smartphones, tablets, and wearables. Its offerings include the Barcode Scanner SDK, which transforms devices into enterprise-grade scanning tools, and the MatrixScan feature that enhances recognition processes for retail and logistics. Scandit's solutions are utilized across multiple industries, such as retail, healthcare, and manufacturing, to support applications like mobile shopping, inventory management, and asset tracking. The company's technology also incorporates augmented reality capabilities, providing real-time information overlays to improve user experience. Scandit aims to enhance operational efficiency and customer satisfaction for organizations, serving a diverse clientele that includes well-known brands.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, the company utilizes the repeatome—a previously overlooked segment of genetic material—to create novel treatment options. By identifying multiple drug targets and advancing several discovery programs, ROME Therapeutics aims to tap into this unexplored area of biology. The organization has assembled a team of experts in oncology, immunology, virology, and machine learning to lead its research and development efforts, which are designed to provide healthcare professionals with effective new treatments for patients suffering from these conditions.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

TScan Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative T cell receptor (TCR) engineered therapies to combat various cancers. Based in Waltham, Massachusetts, the company focuses on TCR-T therapies for both liquid cancers and solid tumors. Its lead candidates, TSC-100 and TSC-101, are designed to address hematologic malignancies, specifically targeting residual leukemia and preventing relapse after hematopoietic stem cell transplantation. In addition, TScan is advancing a multiplexed TCR-T therapy program aimed at treating a range of solid tumors. The company's proprietary platform identifies clinically relevant T cell antigens and minimizes off-target effects, enhancing the precision of its therapies. Founded in 2018, TScan Therapeutics is committed to improving outcomes for patients with serious diseases.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

TScan Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative T cell receptor (TCR) engineered therapies to combat various cancers. Based in Waltham, Massachusetts, the company focuses on TCR-T therapies for both liquid cancers and solid tumors. Its lead candidates, TSC-100 and TSC-101, are designed to address hematologic malignancies, specifically targeting residual leukemia and preventing relapse after hematopoietic stem cell transplantation. In addition, TScan is advancing a multiplexed TCR-T therapy program aimed at treating a range of solid tumors. The company's proprietary platform identifies clinically relevant T cell antigens and minimizes off-target effects, enhancing the precision of its therapies. Founded in 2018, TScan Therapeutics is committed to improving outcomes for patients with serious diseases.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Arrakis Therapeutics, Inc. is a biopharmaceutical company focused on developing a proprietary platform for drug discovery that targets ribonucleic acid (RNA). The company aims to identify new RNA targets and create small-molecule drug candidates, primarily addressing cancer and other genetically validated diseases. Its innovative platform combines advanced RNA bioinformatics, structural tools, chemical biology, and medicinal chemistry, facilitating the development of RNA-targeted small molecules (rSMs). Additionally, Arrakis offers SHAPEware, a software tool designed to predict RNA secondary structures and potential ligand-binding sites. Founded in 2015, Arrakis Therapeutics is headquartered in Waltham, Massachusetts, and its work enables improved treatment options for various conditions, including neurological disorders and rare genetic diseases.

Lola Travel Company, Inc. specializes in corporate travel management through its AI-driven platform, Lola.com. Established in 2015 and headquartered in Boston, Massachusetts, the company simplifies the travel booking process for businesses by offering an intuitive tool for flight and hotel reservations. Lola.com allows users to manage itineraries via a mobile application, providing individual travel profiles, digital travel receipts, and budget tracking services. The platform also supports employee-friendly travel policies, efficient spend reporting for managers, and features that enable team destination sharing and loyalty point accumulation. With 24/7 agent assistance and capabilities for executive assistants to book travel on behalf of others, Lola.com caters to the needs of both employers and business travelers, streamlining the overall travel experience.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Relay Therapeutics, Inc. is a clinical-stage precision medicine company based in Cambridge, Massachusetts, focused on transforming the drug discovery process. The company employs a novel allosteric drug-discovery platform, known as Dynamo, which integrates advanced computational techniques with experimental methods to study protein motion and interactions. This innovative approach enables the identification and development of therapies targeting complex diseases, particularly in oncology. Relay Therapeutics is advancing a pipeline of product candidates, including RLY-1971, a small molecule inhibitor targeting SHP2, RLY-4008, a selective inhibitor of FGFR2 for advanced solid tumors, and RLY-PI3K1047, aimed at mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, the company aims to deliver life-changing therapies to patients by addressing previously intractable targets in precision oncology and genetic diseases.

RightHand Robotics, Inc. specializes in the manufacturing of robotic order-picking systems designed to enhance supply chain logistics and order fulfillment across various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015, the company is headquartered in Cambridge, Massachusetts, with an additional office in Frankfurt, Germany. RightHand Robotics offers innovative solutions like the ReFlex SF, which features a 3D-printed palm equipped with advanced servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that aids in gentle object handling. Their technology enables robots to automatically grasp a wide range of items from bins and cases without the need for extensive data entry or parameter tuning, making their systems cost-effective and adaptable to changing business needs.

Snyk Ltd., established in 2015, specializes in a Software as a Service (SaaS) platform that enhances application security. It focuses on identifying, rectifying, and monitoring known vulnerabilities across critical components of modern applications, including code, open-source libraries, containers, and infrastructure as code. Snyk's offerings, such as Snyk Code (static application security testing), container vulnerability management, and application security management, integrate seamlessly with developers' workflows, improving security posture, productivity, and collaboration. With over 1,200 global customers, including industry leaders like Google and Salesforce, Snyk is recognized for its developer-first approach and strategic partnerships.

Mabl Inc. is an intelligent test automation company based in Boston, Massachusetts, founded in 2016. It offers an automated testing service that leverages machine learning to identify regressions and automatically fix broken tests. The platform provides scriptless testing and integrates seamlessly into the continuous integration and continuous deployment (CI/CD) development lifecycle, allowing software teams to create and maintain reliable, auto-healing tests. By streamlining the testing process, Mabl enables organizations to enhance the speed and quality of their software releases, facilitating faster delivery of high-quality applications while helping developers and testers address bugs before they reach production.

Yesware, Inc. is a technology company that specializes in developing a prescriptive sales platform tailored for startups and sales professionals globally. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware offers an all-in-one toolkit for sales within email platforms such as Outlook and Gmail. This toolkit enables sales professionals to track emails, schedule communications, set reminders, and place calls directly from their inboxes. Yesware's platform is designed to enhance sales productivity by providing advanced analytics, customizable email templates, and integration with customer relationship management systems. It supports both small businesses and large enterprises, helping organizations streamline their sales processes and improve customer engagement. Yesware is trusted by companies like Yelp, Twitter, and Monday.com, and has been installed over 1.2 million times, demonstrating its widespread adoption in the sales industry.

Scandit AG is a technology company specializing in barcode scanning software solutions and mobile computer vision. Founded in 2009 and headquartered in Zurich, Switzerland, with additional offices in the United States and Europe, Scandit develops applications that enable high-performance scanning on various smart devices, including smartphones, tablets, and wearables. Its offerings include the Barcode Scanner SDK, which transforms devices into enterprise-grade scanning tools, and the MatrixScan feature that enhances recognition processes for retail and logistics. Scandit's solutions are utilized across multiple industries, such as retail, healthcare, and manufacturing, to support applications like mobile shopping, inventory management, and asset tracking. The company's technology also incorporates augmented reality capabilities, providing real-time information overlays to improve user experience. Scandit aims to enhance operational efficiency and customer satisfaction for organizations, serving a diverse clientele that includes well-known brands.

Tamr, Inc. is an enterprise data unification company that specializes in providing data management solutions. The company offers a platform that utilizes machine learning combined with human expertise to identify and integrate diverse internal and external data sources, thereby enabling organizations to manage siloed data effectively. Tamr's services include enterprise data preparation, clinical data conversion, procurement optimization, and customer data integration, catering to various sectors such as financial services, life sciences, government, and manufacturing. Founded in 2013 by experienced professionals in the database industry, Tamr is headquartered in Cambridge, Massachusetts, with additional offices in major cities including New York, Seattle, San Francisco, Washington, D.C., and London. The company aims to deliver valuable insights from data, supporting clients in achieving successful business outcomes.

Openbay, Inc. is a company that specializes in providing software-as-a-service (SaaS) solutions for the automotive care industry. Founded in 2011 and based in Cambridge, Massachusetts, Openbay operates an online marketplace that connects vehicle owners with automotive repair professionals. This platform allows users to find, compare, book, and pay for a wide range of vehicle maintenance and repair services, including air conditioning repairs, battery replacements, brake services, oil changes, and tire replacements, among others. The company collaborates with various service providers, including car dealerships, national chains, independent shops, and mobile mechanics. Openbay has received recognition for its innovative approach to making automotive services more accessible and cost-effective for consumers, attracting venture capital backing and media attention from prominent outlets.

Celsius Therapeutics is a biotechnology company focused on developing precision medicines for patients with cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a team of scientists, technologists, computational biologists, clinicians, and drug hunters. Utilizing single-cell genomic analysis and machine learning techniques, Celsius Therapeutics aims to discover and create innovative therapies that can lead to significant improvements in patient outcomes. The company's research efforts are centered on identifying new drug candidates that address unmet medical needs in the therapeutic landscape.

SingleStore, Inc. is a provider of a relational database designed for cloud and on-premises transactions and analytics, catering to global enterprises. Founded in 2011 and headquartered in San Francisco, California, the company offers the SingleStore Managed Service, a cloud database-as-a-service that enables analytics on various cloud platforms, alongside SingleStore DB, a distributed SQL database suitable for both bare metal and hybrid cloud environments. The company focuses on operational analytics and supports modern data platform solutions that encompass IoT analytics, risk management, and customer engagement. SingleStore serves a diverse range of industries, including financial services, media communications, energy and utilities, government, and retail. The company, previously known as MemSQL Inc., rebranded to SingleStore, Inc. in October 2020 and also maintains offices in Seattle, Boston, Portland, Lisbon, and London.

Relay Therapeutics, Inc. is a clinical-stage precision medicine company based in Cambridge, Massachusetts, focused on transforming the drug discovery process. The company employs a novel allosteric drug-discovery platform, known as Dynamo, which integrates advanced computational techniques with experimental methods to study protein motion and interactions. This innovative approach enables the identification and development of therapies targeting complex diseases, particularly in oncology. Relay Therapeutics is advancing a pipeline of product candidates, including RLY-1971, a small molecule inhibitor targeting SHP2, RLY-4008, a selective inhibitor of FGFR2 for advanced solid tumors, and RLY-PI3K1047, aimed at mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, the company aims to deliver life-changing therapies to patients by addressing previously intractable targets in precision oncology and genetic diseases.

Fractyl Health, based in Lexington, Massachusetts, specializes in developing innovative medical device solutions for metabolic diseases, particularly type 2 diabetes and obesity. The company’s primary offering, Revita DMR, is a minimally invasive therapy that utilizes hydrothermal ablation to rejuvenate the duodenal lining, which can become compromised due to high-fat and high-sugar diets. By focusing on durable disease-modifying therapies rather than just symptomatic management, Fractyl Health aims to address the underlying causes of metabolic diseases, improving patient outcomes and reducing healthcare burdens. Founded in 2010 and originally named MedCatalyst, Inc., the company envisions a future where less invasive, device-based therapies provide effective solutions for large populations affected by metabolic disorders.

LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Toast, Inc. is a Boston-based restaurant technology company that specializes in developing an all-in-one point-of-sale and restaurant management platform tailored for the food service and hospitality industries. Founded in 2011, Toast offers a cloud-based system designed specifically for restaurants, enabling functionalities such as tableside ordering, real-time reporting, online ordering, and labor management. The platform serves a diverse clientele, including restaurants, cafés, bars, and bakeries, and supports over 120,000 locations across the United States. Toast generates revenue through software subscription fees, transaction processing commissions, and additional services such as hardware installation and professional support. By facilitating payment transactions on its platform, Toast processed approximately $126 billion in gross volume in 2023, demonstrating its significant role in the restaurant technology landscape.

Evelo Biosciences, Inc., established in 2015, is a biotechnology company based in Cambridge, Massachusetts. It specializes in the discovery and development of a novel class of medicines known as monoclonal microbials, which are orally delivered and designed to modulate systemic immunology and biology by interacting with human cells in the gut. Evelo's pipeline includes EDP1815, currently in a Phase 1b clinical trial for psoriasis and atopic dermatitis, and EDP1503, in a Phase 1/2 study for various cancer types, including colorectal, triple-negative breast, and melanoma. The company aims to apply this innovative approach across a broad range of diseases, including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory conditions, and cancer.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing novel therapies for patients with genetically defined diseases that have significant unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy, a rare condition characterized by progressive muscle wasting and disability. Another key candidate, FTX-6058, aims to upregulate fetal hemoglobin to treat sickle cell disease and beta-thalassemia. Fulcrum is also actively researching drug targets for other genetic disorders, including Duchenne muscular dystrophy and Friedreich ataxia, as well as neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma to explore biological targets in pulmonary disease and with MyoKardia to develop therapies for genetic cardiomyopathies. Founded in 2015, Fulcrum Therapeutics continues to focus on improving patient outcomes in rare disease contexts.

Magenta Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies to enhance stem cell transplantation for patients with blood cancers, genetic diseases, and autoimmune disorders. The company aims to improve the safety and efficacy of stem cell transplants, which are currently high-risk procedures often considered only as a last resort. Its pipeline includes several key product candidates, such as targeted antibody-drug conjugates for transplant conditioning, a novel stem cell mobilization agent, and allogeneic stem cell therapies. Magenta is also exploring collaborations to assess the effectiveness of its therapies in combination with existing treatments, such as gene therapies for sickle cell disease. Founded in 2015 and headquartered in Cambridge, Massachusetts, Magenta Therapeutics seeks to expand the curative potential of stem cell therapies to a broader patient population by addressing the toxicity and long-term side effects associated with current transplant methods.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Desktop Metal, Inc. is a manufacturer of additive manufacturing solutions, specializing in 3D printing technologies for metal and carbon fiber. Founded in 2015 and headquartered in Burlington, Massachusetts, the company offers a range of products, including the Production System for industrial manufacturing, the Shop System for machine and job shops, the Studio System designed for office use, and the Fiber desktop 3D printer. Desktop Metal serves a variety of industries such as automotive, aerospace, healthcare, consumer products, heavy industry, machine design, and research and development. Its innovative systems, materials, and software facilitate on-demand digital mass production, providing the speed, cost-efficiency, and part quality necessary for modern manufacturing. The company markets its solutions across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, with a significant portion of its revenue generated from the Americas.

Lola Travel Company, Inc. specializes in corporate travel management through its AI-driven platform, Lola.com. Established in 2015 and headquartered in Boston, Massachusetts, the company simplifies the travel booking process for businesses by offering an intuitive tool for flight and hotel reservations. Lola.com allows users to manage itineraries via a mobile application, providing individual travel profiles, digital travel receipts, and budget tracking services. The platform also supports employee-friendly travel policies, efficient spend reporting for managers, and features that enable team destination sharing and loyalty point accumulation. With 24/7 agent assistance and capabilities for executive assistants to book travel on behalf of others, Lola.com caters to the needs of both employers and business travelers, streamlining the overall travel experience.

Qwiklabs Inc. is a company that specializes in providing virtual lab environments for software training, enabling developers and IT professionals to gain hands-on experience with cloud technologies, particularly those associated with AWS. Founded in 2012 and headquartered in Carlisle, Massachusetts, Qwiklabs offers a platform that allows clients to create, manage, and operate labs for various applications, including security, big data, and serverless web apps. The platform features a wide array of self-paced labs and AWS-authorized instructor-led training courses, ensuring learners can access real-world scenarios in actual AWS environments. Qwiklabs also provides a flexible pricing model, allowing users to access specific labs or opt for an all-inclusive subscription. Additionally, learners can earn badges and complete quests to enhance their knowledge and credentials in key areas such as AWS Certification Exam preparation and advanced operations. As of November 2016, Qwiklabs operates as a subsidiary of Alphabet Inc.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

Plexxi Inc. is a provider of converged application-defined network infrastructure designed to enhance the performance of applications in software-defined data centers and public/private clouds. The company offers a comprehensive suite of tools, including hardware, management systems, and application integrations, which enable cloud builders to create and manage private, public, and hybrid cloud networks efficiently. Plexxi's solutions focus on optimizing network performance, allowing applications to operate at the speed of business. Founded in 2010 and based in Nashua, New Hampshire, Plexxi operates as a subsidiary of Hewlett Packard Enterprise Company following its acquisition in 2018.

Toast, Inc. is a Boston-based restaurant technology company that specializes in developing an all-in-one point-of-sale and restaurant management platform tailored for the food service and hospitality industries. Founded in 2011, Toast offers a cloud-based system designed specifically for restaurants, enabling functionalities such as tableside ordering, real-time reporting, online ordering, and labor management. The platform serves a diverse clientele, including restaurants, cafés, bars, and bakeries, and supports over 120,000 locations across the United States. Toast generates revenue through software subscription fees, transaction processing commissions, and additional services such as hardware installation and professional support. By facilitating payment transactions on its platform, Toast processed approximately $126 billion in gross volume in 2023, demonstrating its significant role in the restaurant technology landscape.

PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Panorama Education, Inc. is a data analytics company based in Boston, Massachusetts, that focuses on K-12 education. Founded in 2012, the company provides a software-as-a-service (SaaS) platform that enables school districts, charter networks, and state governments to conduct comprehensive surveys of students, parents, teachers, and staff. Through its research-based surveys, Panorama collects valuable feedback on various aspects of the educational environment, including teacher performance and school climate. The platform generates detailed reports that allow educators and administrators to analyze results across different demographics. Additionally, Panorama offers implementation consultation, technical assistance, and training to enhance the effectiveness of its services. By leveraging stakeholder feedback, the company aims to support professional development and improve student outcomes in schools.

Tamr, Inc. is an enterprise data unification company that specializes in providing data management solutions. The company offers a platform that utilizes machine learning combined with human expertise to identify and integrate diverse internal and external data sources, thereby enabling organizations to manage siloed data effectively. Tamr's services include enterprise data preparation, clinical data conversion, procurement optimization, and customer data integration, catering to various sectors such as financial services, life sciences, government, and manufacturing. Founded in 2013 by experienced professionals in the database industry, Tamr is headquartered in Cambridge, Massachusetts, with additional offices in major cities including New York, Seattle, San Francisco, Washington, D.C., and London. The company aims to deliver valuable insights from data, supporting clients in achieving successful business outcomes.

Yesware, Inc. is a technology company that specializes in developing a prescriptive sales platform tailored for startups and sales professionals globally. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware offers an all-in-one toolkit for sales within email platforms such as Outlook and Gmail. This toolkit enables sales professionals to track emails, schedule communications, set reminders, and place calls directly from their inboxes. Yesware's platform is designed to enhance sales productivity by providing advanced analytics, customizable email templates, and integration with customer relationship management systems. It supports both small businesses and large enterprises, helping organizations streamline their sales processes and improve customer engagement. Yesware is trusted by companies like Yelp, Twitter, and Monday.com, and has been installed over 1.2 million times, demonstrating its widespread adoption in the sales industry.

Cockroach Labs, Inc. is a technology company that specializes in developing open-source database software, particularly known for its flagship product, CockroachDB. This cloud-native, distributed SQL database is designed to support the rapid scaling of applications while ensuring resilience against failures, including disk, machine, and datacenter outages. CockroachDB offers strong consistency and ACID transactions, along with an SQL API for efficient data management. The platform is utilized by a diverse range of customers, from small startups to Fortune 500 companies, across various industries such as finance, retail, and media. Founded in 2015, Cockroach Labs is headquartered in New York City, with an additional office in Cambridge, Massachusetts. The company focuses on enabling developers to build robust applications without compromising on performance or reliability.

Recorded Future, Inc. is a threat intelligence company that provides real-time solutions to enhance cybersecurity for organizations. Founded in 2009 and headquartered in Somerville, Massachusetts, with additional offices in McLean, Virginia, and Gothenburg, Sweden, the company leverages patented machine learning technology to analyze data from the open web, dark web, and technical sources. This enables organizations to gain comprehensive insights into potential threats and vulnerabilities, facilitating swift and informed decision-making. Its offerings include tools for threat intelligence teams and security operation center (SOC) teams, as well as specialized services like dark web monitoring, executive cyber protection, and custom intelligence assessments. Additionally, Recorded Future provides integration services that streamline workflows and enhance operational capabilities through real-time alerts and monitoring dashboards. The company’s platform empowers users to respond to security threats more effectively, thereby reducing risks associated with cyberattacks.

Adelphic, Inc. is a company that specializes in a programmatic advertising platform designed to connect brands with audiences across multiple channels. Established in 2011 and based in Waltham, Massachusetts, Adelphic offers a user-friendly campaign management portal that enables non-technical users to plan, create, launch, and optimize their advertising campaigns. Its platform features an Audience Cube tool, which captures large volumes of data to create custom audience segments and insights, and includes predictive performance engine solutions. The technology is fully real-time bidding (RTB) enabled, allowing access to a wide range of inventory providers, thus facilitating meaningful consumer engagements across various devices and formats. Adelphic primarily serves agencies, brands, and large media buyers, and has been operating as a subsidiary of Viant Technology Inc. since early 2017.

Tamr, Inc. is an enterprise data unification company that specializes in providing data management solutions. The company offers a platform that utilizes machine learning combined with human expertise to identify and integrate diverse internal and external data sources, thereby enabling organizations to manage siloed data effectively. Tamr's services include enterprise data preparation, clinical data conversion, procurement optimization, and customer data integration, catering to various sectors such as financial services, life sciences, government, and manufacturing. Founded in 2013 by experienced professionals in the database industry, Tamr is headquartered in Cambridge, Massachusetts, with additional offices in major cities including New York, Seattle, San Francisco, Washington, D.C., and London. The company aims to deliver valuable insights from data, supporting clients in achieving successful business outcomes.

Kensho Technologies, Inc. specializes in analytics, artificial intelligence, machine learning, and data visualization systems tailored for global banks and investment institutions. Founded in 2012 and headquartered in Cambridge, Massachusetts, with additional offices in New York, Virginia, and California, Kensho develops financial analytics software that enables scalable analytics solutions for commercial entities. Its offerings include Kensho Applied Mind, an AI software that enhances decision-making by addressing complex financial inquiries in natural language. The company also operates a national security division known as Koto. As of April 2018, Kensho operates as a subsidiary of S&P Global Inc.

Boston Dynamics, Inc. is an engineering company based in Waltham, Massachusetts, specializing in the design and manufacture of advanced robots and software for human simulation. Founded in 1992 as a spin-off from the Massachusetts Institute of Technology, the company has gained recognition for its innovative robots that mimic animal movement, such as Spot, a quadruped robot, and Atlas, a humanoid robot. These robots are equipped with cutting-edge mobility, dexterity, and intelligence, allowing them to perform tasks in challenging environments, including industrial plants, construction sites, and warehouses. Boston Dynamics also develops software for human simulation, which is utilized in various training applications, including law enforcement and military operations. The company collaborates with organizations globally, providing solutions to some of the most complex challenges in automation and robotics.

Yesware, Inc. is a technology company that specializes in developing a prescriptive sales platform tailored for startups and sales professionals globally. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware offers an all-in-one toolkit for sales within email platforms such as Outlook and Gmail. This toolkit enables sales professionals to track emails, schedule communications, set reminders, and place calls directly from their inboxes. Yesware's platform is designed to enhance sales productivity by providing advanced analytics, customizable email templates, and integration with customer relationship management systems. It supports both small businesses and large enterprises, helping organizations streamline their sales processes and improve customer engagement. Yesware is trusted by companies like Yelp, Twitter, and Monday.com, and has been installed over 1.2 million times, demonstrating its widespread adoption in the sales industry.

Openbay, Inc. is a company that specializes in providing software-as-a-service (SaaS) solutions for the automotive care industry. Founded in 2011 and based in Cambridge, Massachusetts, Openbay operates an online marketplace that connects vehicle owners with automotive repair professionals. This platform allows users to find, compare, book, and pay for a wide range of vehicle maintenance and repair services, including air conditioning repairs, battery replacements, brake services, oil changes, and tire replacements, among others. The company collaborates with various service providers, including car dealerships, national chains, independent shops, and mobile mechanics. Openbay has received recognition for its innovative approach to making automotive services more accessible and cost-effective for consumers, attracting venture capital backing and media attention from prominent outlets.

Yesware, Inc. is a technology company that specializes in developing a prescriptive sales platform tailored for startups and sales professionals globally. Founded in 2010 and headquartered in Boston, Massachusetts, with an additional office in San Francisco, Yesware offers an all-in-one toolkit for sales within email platforms such as Outlook and Gmail. This toolkit enables sales professionals to track emails, schedule communications, set reminders, and place calls directly from their inboxes. Yesware's platform is designed to enhance sales productivity by providing advanced analytics, customizable email templates, and integration with customer relationship management systems. It supports both small businesses and large enterprises, helping organizations streamline their sales processes and improve customer engagement. Yesware is trusted by companies like Yelp, Twitter, and Monday.com, and has been installed over 1.2 million times, demonstrating its widespread adoption in the sales industry.

SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

Objective Logistics, Inc. is a provider of an artificial intelligence-driven labor management platform tailored for the retail and hospitality sectors. Founded in 2009 and based in Boston, Massachusetts, the company offers MUSE, a web-based software solution designed to enhance staff performance through motivation, measurement, and mentorship. MUSE employs customizable metrics to evaluate employee performance, including sales figures and behavioral attributes. The platform features custom contests, leaderboards, and analytics reports that equip teams with insights to improve productivity. Additionally, it offers staff scheduling and forecasting tools to streamline operations. Objective Logistics aims to boost sales and enhance the guest experience across various industries, while also rewarding top performers with preferred shifts and other non-monetary incentives.

Adelphic, Inc. is a company that specializes in a programmatic advertising platform designed to connect brands with audiences across multiple channels. Established in 2011 and based in Waltham, Massachusetts, Adelphic offers a user-friendly campaign management portal that enables non-technical users to plan, create, launch, and optimize their advertising campaigns. Its platform features an Audience Cube tool, which captures large volumes of data to create custom audience segments and insights, and includes predictive performance engine solutions. The technology is fully real-time bidding (RTB) enabled, allowing access to a wide range of inventory providers, thus facilitating meaningful consumer engagements across various devices and formats. Adelphic primarily serves agencies, brands, and large media buyers, and has been operating as a subsidiary of Viant Technology Inc. since early 2017.

HubSpot, Inc., established in 2005 and headquartered in Cambridge, Massachusetts, specializes in providing a comprehensive, cloud-based software platform for businesses worldwide. This platform integrates marketing, sales, and customer service applications, including CRM, SEO, content management, messaging, marketing automation, analytics, and more. HubSpot serves mid-market business-to-business companies, helping them attract visitors, convert leads, and close customers through its inbound marketing approach.